U.S. Serial No. 09/827,302 Filed: April 5, 2001 Response to Second Office Action Page 2 of 2

DRAFT

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

- 1. (Previously presented) A method for treating a human with cancer, comprising administering to the human with cancer between approximately 10^{-8} mg of neuraminidase.
- 2. (Previously presented) The method of Claim 1, wherein the composition comprises neuraminidase dissolved in a phenol-saline solution.

Claim 3 cancelled.

- 4. (Previously presented) The method of Claim 1, wherein the neuraminidase composition is administered systemically.
- 5. (Previously presented) The method of Claim 1, wherein the neuraminidase composition is administered by subcutaneous injection, intramuscular injection, intravenous injection, nasal administration, sublingual administration or transdermal administration.
- 6. (Previously presented) The method of Claim 5, wherein the neuraminidase composition is administered sublingually.
- 7. (Previously presented) The method of Claim 5, wherein the neuraminidase composition is administered nasally.
- 8. (Previously presented) The method of Claim 1, wherein cancer is a solid tumor.

U.S. Serial No. 09/827,302 Filed: April 5, 2001 Response to Second Office Action Page 3 of 3

DRAFT

9. (Previously presented) The method of Claim 8, wherein cancer is prostrate cancer, pancreatic cancer, melanoma, breast cancer, colon cancer, lymphoma, esophageal cancer, lung cancer, testicular cancer, or brain cancer.

Claims 10 and 11 cancelled.

- 12. (Currently Amended) The method of Claim 1, wherein the neuraminidase is administered periodically intermittently.
- 13. (Previously presented) The method of Claim 1, wherein less than approximately 10⁻² mg neuraminidase is administered.
- 14. (Previously presented) The method of Claim 1, wherein approximately 10^{-3} mg to 10^{-7} mg neuraminidase is administered.
- 15. (Previously presented) The method of Claim 1, wherein approximately 10^{-4} mg neuraminidase is administered.
- 16. (New) The method of Claim 1, wherein the neuraminidase is administered 1 to 8 times per day.